Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-04-06
DOI
10.3389/fimmu.2022.845499
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
- (2021) Franziska Blaeschke et al. Blood Cancer Journal
- Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells
- (2021) Songbo Zhao et al. Journal for ImmunoTherapy of Cancer
- TIM-3 in Leukemia; Immune Response and Beyond
- (2021) Mahnaz Rezaei et al. Frontiers in Oncology
- Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients
- (2020) Franziska Blaeschke et al. LEUKEMIA
- CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma
- (2020) Hui Liu et al. CLINICAL CANCER RESEARCH
- Mechanisms of resistance to CAR T cell therapy
- (2019) Nirali N. Shah et al. Nature Reviews Clinical Oncology
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
- (2018) Marco Ruella et al. NATURE MEDICINE
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
- (2018) Elena J. Orlando et al. NATURE MEDICINE
- PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma
- (2018) Felicitas Rataj et al. Frontiers in Immunology
- Teaching an old dog new tricks: next-generation CAR T cells
- (2018) Nicholas Tokarew et al. BRITISH JOURNAL OF CANCER
- FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
- (2018) Maura C. O’Leary et al. CLINICAL CANCER RESEARCH
- Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients
- (2017) Yang Zhang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy
- (2015) Sebastian Kobold et al. JNCI-Journal of the National Cancer Institute
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy
- (2015) Sebastian Kobold et al. JNCI-Journal of the National Cancer Institute
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion
- (2012) Manu Rangachari et al. NATURE MEDICINE
- Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways
- (2011) J. Lee et al. MOLECULAR AND CELLULAR BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More